Article

Herpetic keratitis treatment NDA accepted by FDA

A new drug application (NDA) has been accepted for review by the FDA for the approval of a treatment (ganciclovir, Sirion Therapeutics) for herpetic keratitis.

Tampa, FL-A new drug application (NDA) has been accepted for review by the FDA for the approval of a treatment (ganciclovir, Sirion Therapeutics) for herpetic keratitis.

"Herpes simplex keratitis remains one of the leading causes of corneal blindness and corneal transplants in the United States. If approved by the FDA, ganciclovir ophthalmic gel would become the first topical ophthalmic antiviral treatment launched in the U.S. in almost three decades,” said Barry Butler, chief executive officer of Sirion Therapeutics. “This product would provide a significant new option for physicians in the treatment of patients with herpetic keratitis."

Four randomized, multicenter trials assessed the efficacy and safety comparing the treatment with another treatment (acyclovir, GlaxoSmithKline), both of which are used outside the United States to treat herpetic keratitis.

Study results showed that the new drug is just as effective as the treatment it was compared with, and that the tolerability of the new drug was superior, particularly with regard to blurring and stinging or burning sensations after instillation. Additionally, since the new drug is formulated as an aqueous gel, it allows for prolonged contact time with the corneal surface, according to investigators.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.